Bibliographic Details
| Title: |
Janux's T-cell engager makes waves, again, with 'best-in-class' data drop: analyst. |
| Authors: |
Becker, Zoey (AUTHOR) |
| Source: |
FierceBiotech. 12/3/2024, pN.PAG-N.PAG. 1p. |
| Subject Terms: |
Therapeutics, Prostate cancer, T cells, Cancer treatment |
| Abstract: |
Among patients with heavily pretreated prostate cancer, all 16 patients who received JANX007 achieved a 50% decline in prostate-specific antigens. [ABSTRACT FROM AUTHOR] |
|
Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Business Source Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
